Curis (CRIS) 10-K2019 FY Annual report

Filed: 19 Mar 20, 4:28pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AbbVie, Advenchen, alpelisib, antibody, argument, Asana, ascending, Aspire, AUM, basket, Baxter, Beijing, bimiralisib, BioMed, Blanver, borrow, borrowing, Boryung, carboxyamidotriazole, categorized, Celon, cessation, chemoradiation, Cleveland, CMG, composed, concession, contended, contra, count, Cyclene, dactolisib, Daiichi, Dainippon, database, departure, district, domatinostat, double, Eddingpharm, EDO, Endo, EOC, exhaust, Fabre, fearful, feature, float, Foreland, Formosa, Fosun, Germany, HaiHe, hand, HanX, Hayden, heard, Hedging, Helsinn, HGBL, HIPPA, HitGen, holdover, homology, Honsha, Hutchison, ImmuNext, implicit, impute, imputed, Inflection, inseverable, iOnctura, Janssen, Jiatan, JonesTrading, kappa, Kazia, Kirin, Knight, Kymera, Kyowa, landlord, Lastly, left, linperlisib, lmmunotherapy, lock, lowest, Lynkcell, MediTech, MEKanistic, Menarini, Microbio, mid, Minister, miransertib, monoclonal, multimarket, Mundipharma, namodenoson, Nanjing, nontransferable, Northern, NovaMedica, Novonex, Noxopharm, nsNSCLC, Nuance, Ohara, Onconova, OnKure, orotate, Otsuka, outbreak, PA, pancreatic, parsaclisib, paxalisib, penalty, Petra, pharmacodynamic, Pharmatech, Pierre, Pint, PIQRAY, Piqur, pocket, pre, procuring, prostate, protracted, randomized, reconsideration, Recursion, release, remanded, resminostat, respiratory, Restorbio, Rhizen, Sanhome, Sankyo, SciClone, serabelisib, Servier, Shenzhen, SignalRx, SME, sooner, Specialised, spread, Spring, ST, strongly, Sumitomo, Supreme, SymBio, syndrome, Tactical, tenalisib, tinostamustine, trailing, turn, unconstitutional, unwilling, upholding, upregulated, Valley, voxtalisib, widespread, Yakult, YingLi

Removed: Amgen, analyzed, auction, convert, CurisTM, deduction, depreciated, discounted, escalate, exit, hospital, knowledgeable, maximize, minimize, noncancellable, Nonstatutory, overseeing, participant, prepay, projection, realizable, Realty, SAB, taladegib, trust, underwritten, weighting, wrote

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated CRIS transcripts

CRIS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(b) OF THE EXCHANGE ACT AND 18 U.S.C. SECTION 1350

In connection with the Annual Report on Form 10-K of Curis, Inc. (the “Company”) for the period ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, James Dentzer, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:	March 19, 2020	/S/ JAMES E. DENTZER
		James Dentzer
		President and Chief Executive Officer
		(Principal Executive Officer)